Essex Investment Management Co. LLC Acquires Shares of 474,955 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Essex Investment Management Co. LLC acquired a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 474,955 shares of the company’s stock, valued at approximately $1,610,000.

A number of other institutional investors also recently modified their holdings of XERS. Wealth Enhancement Advisory Services LLC acquired a new stake in Xeris Biopharma in the 3rd quarter valued at $35,000. R Squared Ltd acquired a new position in shares of Xeris Biopharma during the fourth quarter valued at about $42,000. Quantbot Technologies LP acquired a new position in shares of Xeris Biopharma during the third quarter valued at about $44,000. Raymond James Financial Inc. bought a new stake in shares of Xeris Biopharma during the fourth quarter worth about $45,000. Finally, Sunpointe LLC acquired a new stake in shares of Xeris Biopharma in the 4th quarter worth about $71,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Stock Performance

NASDAQ:XERS opened at $4.24 on Monday. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.69 and a 52 week high of $4.50. The firm has a 50-day moving average price of $3.57 and a two-hundred day moving average price of $3.26. The firm has a market cap of $632.10 million, a price-to-earnings ratio of -9.42 and a beta of 2.32.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday. Finally, Piper Sandler reissued a “neutral” rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.